(Abstracted from Gynecol Oncol 153 (2019) 521–529)
On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)–associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.
Department of Family and Community Medicine, Obstetrics and Gynecology, University of Missouri Kansas City, Kansas City, MO (D.M.H.); Department of Obstetrics and Gynaecology, Helsinki University Hospital and Helsinki University, Helsinki, Finland (P.N.); Department of Obstetrics and Gynaecology, University Hospital Antwerp, Antwerp, Belgium (G.D.); Department of Obstetrics and Gynecology, Albert Einstein Cancer Center and Montefiore Medical Center, Bronx, NY (M.H.E.); Center of Excellence in Women’s Health at the University of Arizona, Tucson, AZ (F.G.); Department of Obstetrics and Gynecology, University of Alabama, Birmingham, AL (W.K.H.); Surgical Pathology, Department of Pathology, University of Virginia Health System, University of Virginia, Charlottesville, VA (M.H.S.); Roche Pharmaceutical Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland (K.G.); Roche Pharmaceutical Research & Early Development, Roche Innovation Center New York, New York City, NY (G.A., E.C.); and Departments of Medical Affairs (J.-M.L.) and Biostatistics (B.B.), Transgene S.A., Illkirch-Graffenstaden, France